Performance of the Wixela Inhub Inhaler Using Severe Chronic Obstructive Pulmonary Disease Patient Inhalation Profiles.

Wixela Inhub (trademarks of Viatris, Inc.) is a dry powder inhaler (DPI) that delivers a fixed-dose combination of fluticasone propionate and salmeterol and is approved as a generic equivalent to Advair Diskus (trademarks of GlaxoSmithKline plc) for the treatment of asthma and chronic obstructive pulmonary disease (COPD). The dosing performance of DPIs is dependent on the patient's inspiratory capability, which may be impacted in disease populations such as those with severe COPD.

The face-in-the-crowd effect: Threat detection versus iso-feature suppression and collinear facilitation.

Are people biologically prepared for the rapid detection of threat posed by an angry facial expression, even when it is conveyed in the form of a schematic line drawing? Based on visual search times, the current literature would suggest that the answer is yes. But are there low-level explanations for this effect? Here, we present visual search results for schematic faces using current best practice, based on a concentric search array and set size manipulation. Using this approach, we replicate the classic search advantage for angry over happy faces.